Affinage

B4GALT1

Beta-1,4-galactosyltransferase 1 · UniProt P15291

Length
398 aa
Mass
43.9 kDa
Annotated
2026-06-09
39 papers in source corpus 20 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

B4GALT1 is a Golgi-resident β-1,4-galactosyltransferase that adds galactose to N-glycans and whose activity is subject to assembly-level control: wild-type enzyme exists in monomer–homodimer equilibrium, with catalytic-residue surfaces mediating a silencing homomer, while interaction with ST6GAL1 through noncatalytic charged surfaces forms heteromers required for full sequential N-glycan modification (PMID:31395657, PMID:30352055). Complex formation with the UDP-galactose transporter SLC35A2 is gated by nucleotide-sugar availability, coupling enzyme output to substrate supply (PMID:40230451). A p.Asn352Ser variant lowers galactosyltransferase activity by ~50%, reducing galactosylation of ApoB100, fibrinogen, IgG, and transferrin and lowering LDL-C and fibrinogen in knock-in mice, establishing B4GALT1 as a regulator of lipoprotein and coagulation factor metabolism (PMID:34855475); consistent with this, loss of B4GALT1-dependent galactosylation hypoglycosylates and inactivates CETP, altering HDL homeostasis (PMID:31800099). Beyond bulk glycoprotein processing, B4GALT1 site-specifically glycosylates defined substrates to control their stability, ligand binding, or trafficking: it N-glycosylates and stabilizes PD-L1, TAZ, CDK11p110, and IL-1R1 (at N193), destabilizes PPARγ, modifies integrin α6/β1 to restrain laminin binding, and modifies the TGF-β receptor as required for galectin-8 recognition (PMID:37303063, PMID:33309857, PMID:42002123, PMID:41860570, PMID:37907465, PMID:39231945). Independent of catalysis, B4GALT1 binds LRP5/6 in the Golgi and retains them intracellularly to attenuate WNT/β-catenin signaling, a retention antagonized by Wntless engagement (PMID:41182165). Through these substrate-specific actions B4GALT1 influences immune escape, inflammatory and ferroptotic signaling, integrin-driven migration, and chemoresistance across multiple cancer and disease contexts (PMID:37303063, PMID:37907465, PMID:42002123, PMID:41860570).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2018 High

    Resolved whether and how B4GALT1 self-assembles and links its quaternary structure to catalysis, establishing the conformational basis of substrate binding.

    Evidence X-ray crystallography of the wild-type homodimer plus catalytic-residue mutagenesis and live-cell FRET

    PMID:30352055

    Open questions at the time
    • Does not define how the silencing homomer is relieved in vivo
    • No structure of the active heteromer
  2. 2019 High

    Showed that B4GALT1 and ST6GAL1 form catalytically required heteromers via distinct surfaces, explaining how sequential N-glycan elaboration is organized within the Golgi.

    Evidence Molecular docking, mutagenesis screens, and high-throughput FRET in live cells

    PMID:31395657

    Open questions at the time
    • Interaction surfaces inferred from docking/FRET rather than a co-structure
    • Stoichiometry and dynamics of the heteromer in situ unresolved
  3. 2019 Medium

    Connected B4GALT1 galactosylation to a specific clinical lipoprotein phenotype by demonstrating CETP hypogalactosylation and reduced activity in CDG patients.

    Evidence Isoelectric focusing, CETP glycoform western blot, and activity assays in patient plasma

    PMID:31800099

    Open questions at the time
    • Does not prove direct CETP modification by B4GALT1
    • Causality to HDL particle size inferred from patient correlation
  4. 2021 High

    Established a causal, quantitative link between B4GALT1 enzymatic activity and systemic lipoprotein/coagulation metabolism through a hypomorphic human variant and a knock-in mouse.

    Evidence In vitro activity assay of mutant vs WT, serum N-glycan profiling, and 353Ser knock-in mice

    PMID:34855475

    Open questions at the time
    • Specific glycoproteins driving the LDL-C/fibrinogen effects not pinpointed
    • Tissue-of-origin for the serum phenotype unresolved
  5. 2023 High

    Identified site-specific protein substrates of B4GALT1 (integrin α6/β1), showing glycosylation tunes integrin–laminin binding and tumor cell invasion.

    Evidence Mass spectrometry substrate ID, GSL-II lectin pull-down, KO/KD, antibody rescue, and lung metastasis model

    PMID:37907465

    Open questions at the time
    • Exact glycan structures on each integrin not mapped
    • Mechanism linking altered glycans to affinity not structurally defined
  6. 2023 Medium

    Extended B4GALT1 function to immune evasion by showing it stabilizes PD-L1 directly and TAZ to drive PD-L1 transcription.

    Evidence Glycosylation and protein-stability assays, transcriptional reporters, and loss-of-function studies

    PMID:37303063

    Open questions at the time
    • Glycosylation sites on PD-L1/TAZ not defined
    • Direct vs indirect stabilization not fully separated
  7. 2026 High

    Demonstrated substrate- and site-specific glycosylation governing inflammatory (IL-1R1 N193) and metabolic/ferroptotic (PPARγ) signaling, broadening the disease reach of B4GALT1.

    Evidence Co-IP, PNGase F, site-directed mutagenesis, conditional/AAV knockdown mice in OA and MASLD models

    PMID:41860570 PMID:42002123

    Open questions at the time
    • PPARγ glycosylation site not specified
    • How glycosylation flips stability up (IL-1R1) versus down (PPARγ) is unexplained
  8. 2025 Medium

    Revealed a catalysis-independent trafficking role: B4GALT1 retains LRP5/6 in the Golgi to dampen WNT signaling, with Wntless competing for the interaction.

    Evidence Co-IP, cell surface translocation assays, and LGK974 pharmacology

    PMID:41182165

    Open questions at the time
    • Whether retention requires galactosyltransferase activity unresolved
    • Structural basis of B4GALT1–LRP5/6 and B4GALT1–Wntless binding unknown
  9. 2025 Medium

    Showed enzyme function is metabolically gated, with UDP-Gal availability controlling B4GALT1–SLC35A2 complex assembly.

    Evidence CRISPR knockout of GALE/GALT, NanoBiT PPI assay, and N-glycan profiling in HEK293T

    PMID:40230451

    Open questions at the time
    • Mechanism by which UDP-Gal promotes complex formation not defined
    • Physiological conditions under which this gating operates unclear
  10. 2025 Medium

    Mapped a broad regulatory network (transcriptional and post-transcriptional) positioning B4GALT1 as both an oncogenic effector and context-dependent tumor suppressor controlling chemoresistance.

    Evidence Reporter, RNAi/overexpression rescue, Co-IP, and ubiquitination assays across leukemia, prostate, and esophageal cancer models

    PMID:23024026 PMID:27516205 PMID:27797721 PMID:32902124 PMID:40097806

    Open questions at the time
    • Context-dependence of oncogenic vs suppressor roles not reconciled
    • Many links are correlative or single-lab
  11. 2025 Medium

    Preprint evidence proposes B4GALT1 galactosylates TCR/CD8 to limit T-cell activation and elongates NOTCH O-glucose glycans to modulate Notch signaling, expanding its substrate repertoire to immune receptors and developmental signaling.

    Evidence CRISPR screens with AP-MS substrate ID and rescue (TCR/CD8); MS, mutagenesis, and Notch reporters (NOTCH1/3) — both preprints

    Open questions at the time
    • Not peer-reviewed
    • TCR/CD8 and NOTCH substrate claims await independent confirmation

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how B4GALT1 achieves substrate selectivity that produces opposite fates (stabilization vs destabilization) and how catalytic versus non-catalytic (trafficking) functions are partitioned in vivo.
  • No structural model of substrate-specific recognition
  • Catalysis-dependent vs catalysis-independent roles not cleanly separated
  • Glycan-structure-to-phenotype mapping incomplete

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 5 GO:0140096 catalytic activity, acting on a protein 5
Localization
GO:0005794 Golgi apparatus 3
Pathway
R-HSA-392499 Metabolism of proteins 4 R-HSA-162582 Signal Transduction 2 R-HSA-168256 Immune System 2
Partners
CDK11IL1R1LRP5LRP6SLC35A2ST6GAL1UBE2Q1

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2019 B4GALT1 and ST6GAL1 interact via highly charged noncatalytic surfaces (leaving active sites exposed), forming heteromers in the Golgi that are required for their full catalytic activity in sequential N-glycan modification. B4GALT1 uses its active-site surface for homomeric assembly, which silences its catalytic activity, whereas ST6GAL1 uses the same noncatalytic surface for both homomers and heteromers. Molecular docking simulations, mutagenesis screens, high-throughput FRET analyses in live cells, structural modeling The Journal of biological chemistry High 31395657
2018 Wild-type human B4GALT1 exists as a homodimer in dynamic equilibrium with monomer; crystal structures revealed B4GALT1 in both open and closed conformations of the Trp loop and lid regions responsible for donor and acceptor substrate binding. Targeted mutagenesis of key catalytic amino acids impaired homomer formation in vivo, linking catalytic residues to dimer assembly. X-ray crystallography (crystal structure of wild-type homodimer), targeted mutagenesis, FRET assays in live cells PloS one High 30352055
2021 A missense variant p.Asn352Ser in the functional domain of B4GALT1 reduces galactosyltransferase activity by ~50% compared to wild-type. Carriers show decreased galactosylation and sialylation of ApoB100, fibrinogen, IgG, and transferrin in serum, and B4galt1 353Ser knock-in mice show decreases in LDL-C and fibrinogen, establishing B4GALT1 galactosyltransferase activity as a regulator of lipoprotein and coagulation factor metabolism. In vitro galactosyltransferase activity assay with mutant vs. wild-type protein, N-linked glycan profiling of human serum, knock-in mouse model Science (New York, N.Y.) High 34855475
2023 B4GALT1 directly mediates N-linked glycosylation of PD-L1 protein, preventing its proteasomal degradation (posttranscriptional stabilization). Additionally, B4GALT1 stabilizes TAZ protein via glycosylation, which in turn activates CD274 (PD-L1) transcription, thereby promoting immune escape in lung adenocarcinoma. In vitro and in vivo functional/mechanistic experiments including glycosylation assays, protein stability assays, transcriptional reporter assays, loss-of-function studies Journal of experimental & clinical cancer research : CR Medium 37303063
2020 B4GALT1 interacts with and stabilizes CDK11p110 via N-linked glycosylation, downstream of p65 transcriptional upregulation of B4GALT1, forming a p65-B4GALT1-CDK11p110 signaling axis that promotes chemoresistance in pancreatic ductal adenocarcinoma. Co-immunoprecipitation, glycosylation assays, genetic perturbation of B4GALT1 in cell lines, orthotopic PDAC mouse model Cancer letters Medium 33309857
2023 B4GALT1 modifies the N-glycans of integrin α6 and integrin β1, and its loss increases laminin-binding activity of these integrins, promoting HCC cell migration and invasion. Integrins α6 and β1 were identified as main protein substrates of B4GALT1 by mass spectrometry and GSL-II lectin pull-down. Mass spectrometry-based substrate identification, Griffonia simplicifolia lectin II (GSL-II) pull-down, B4GALT1 knockdown/knockout, integrin-blocking antibody rescue experiments, in vivo lung metastasis model Oncogenesis High 37907465
2019 In B4GALT1-CDG patients, cholesteryl ester transfer protein (CETP) is hypoglycosylated (specifically hypogalactosylated) and exhibits reduced enzymatic activity, resulting in large HDL particles and altered lipoprotein homeostasis, directly linking B4GALT1-mediated galactosylation to CETP function. Isoelectric focusing, western blot of CETP glyco-isoforms, CETP activity assay in patient plasma vs. controls Journal of inherited metabolic disease Medium 31800099
2025 B4GALT1 interacts with LRP5/6 in the Golgi, causing their retention and reducing LRP5/6 surface translocation, thereby attenuating WNT/β-catenin signaling. B4GALT1 also binds Wntless; Wnt secretion occupying Wntless antagonizes B4GALT1-mediated LRP5/6 retention. Pharmacological uncoupling of Wnt/Wntless with LGK974 enhances LRP5/6 Golgi retention. Co-immunoprecipitation, cell surface translocation assays, pharmacological inhibition (LGK974), loss-of-function studies The Journal of cell biology Medium 41182165
2026 B4GALT1 directly interacts with IL-1R1 and promotes its N-linked glycosylation specifically at the N193 site, thereby enhancing IL-1R1 protein stability and downstream inflammatory signaling in chondrocytes. AAV-mediated knockdown of B4GALT1 in vivo reduced IL-1R1 protein levels and attenuated cartilage degeneration. Co-immunoprecipitation, PNGase F treatment, site-directed mutagenesis (N193 site), AAV-mediated in vivo knockdown, DMM mouse OA model Cellular signalling High 42002123
2026 B4GALT1-mediated N-glycosylation of PPARγ destabilizes PPARγ protein; B4GALT1 deficiency impairs PPARγ N-glycosylation, leading to PPARγ stabilization, which transcriptionally represses ACSL4, thereby reducing lipid peroxidation and ferroptosis in hepatocytes during MASLD progression. Hepatocyte-specific B4galt1-knockout mice (CDAHFD model), N-glycosylation assays, gene expression analysis, PPARγ overexpression rescue experiment Hepatology communications Medium 41860570
2025 Knockout of GALE (UDP-galactose 4'-epimerase), which reduces intracellular UDP-Gal levels, diminishes the ability of the UDP-Gal transporter SLC35A2 to form homomers and to interact with B4GALT1 in the Golgi, indicating that nucleotide sugar availability regulates B4GALT1-SLC35A2 complex formation. CRISPR/Cas9 knockout of GALE and GALT in HEK293T cells, NanoBiT protein-protein interaction assay, N-glycan profiling Frontiers in molecular biosciences Medium 40230451
2012 B4GALT1 knockdown in K562/ADR leukemia cells downregulated the Hedgehog signaling pathway and reversed multidrug resistance in vitro and in vivo, identifying a functional link between B4GALT1-mediated galactosylation and Hedgehog pathway activity in chemoresistance. RNA interference knockdown, enzyme activity assays, lectin blotting, in vitro drug sensitivity assays, in vivo tumor models IUBMB life Medium 23024026
2016 SOCS3 upregulates miR-124-3p, which targets B4GALT1 mRNA, forming a SOCS3/miR-124-3p/B4GALT1 axis that regulates growth and chemosensitivity of CML cells. Luciferase reporter assay confirmed B4GALT1 as a direct target of miR-124-3p. Luciferase reporter assay, qPCR, western blotting, CCK-8 assay, tumorigenicity assays in nude mice Journal of hematology & oncology Medium 27516205
2016 ZFX transcription factor positively regulates B4GALT1 expression in leukemic cells; ZFX silencing decreases B4GALT1 expression and glycoprotein galactosylation. Overexpression of B4GALT1 restored growth and drug resistance in ZFX-silenced cells, placing B4GALT1 downstream of ZFX. RNAi silencing of ZFX, gene expression analysis, lectin blot assay for galactosylation, B4GALT1 overexpression rescue Acta biochimica et biophysica Sinica Medium 27797721
2020 AKR1C3 interacts with AR-V7 protein in CRPC cells, and this complex represses B4GALT1 expression; B4GALT1 is identified as a tumor suppressor gene in prostate cancer downstream of this complex. The AKR1C3/AR-V7 complex also reciprocally inhibits each other's protein degradation. Co-immunoprecipitation (AKR1C3/AR-V7 interaction), gene expression analysis, in vitro and in vivo tumor growth assays Journal of cellular and molecular medicine Medium 32902124
2025 NOLC1 acts as a transcription factor to activate B4GALT1 transcriptional expression; SPOP (E3 ubiquitin ligase adaptor) mediates ubiquitination and degradation of NOLC1. ECa-associated SPOP mutants abrogate NOLC1 ubiquitination, leading to NOLC1 accumulation and B4GALT1 upregulation, causing abnormal glycosylation and paclitaxel resistance. Co-IP for SPOP-NOLC1 interaction, ubiquitination assays, transcriptional reporter assays, B4GALT1 knockdown rescue, in vitro and in vivo functional assays Oncogene Medium 40097806
2024 Galectin-8 interacts with the type II TGF-β receptor and competes with TGF-β binding, suppressing TGF-β-driven EMT and CRC metastasis. The anti-migratory effect of galectin-8 depends on B4GALT1, which modifies N-glycans on TGF-β receptor, establishing B4GALT1 as required for galectin-8 ligand recognition at the TGF-β receptor. Co-immunoprecipitation (galectin-8/TGF-βRII), B4GALT1 depletion experiments, migration assays, intra-splenic injection tumor model Cell death & disease Medium 39231945
2025 B4GALT1 galactosylates TCR and CD8 co-receptor components on the CD8+ T-cell surface, and this galactosylation reduces the interaction between TCR and CD8 that is essential for TCR activation. B4GALT1 inactivation enhances TCR-T cell functions but has no effect on CAR-T cells. Substrates were systematically identified by affinity purification and mass spectrometry. CRISPR/Cas9 genome-wide and custom screens, affinity purification-mass spectrometry for substrate identification, TCR-CD8 fusion protein rescue, syngeneic mouse tumor model bioRxivpreprint Medium
2025 B4GALT1 catalyzes galactose elongation of O-glucose glycans specifically on NOTCH1 EGF10 (and NOTCH3 EGF9), forming a 3'-sialyllactose-like structure in cooperation with ST3GAL4. This site-specific elongation significantly impacts NOTCH1 ligand binding and signal transduction. Mutagenesis identified the amino acid at position -2 of the fourth cysteine as critical for galactose elongation. Mass spectrometry for modification identification, site-directed mutagenesis, ligand-binding assays, Notch signaling reporter assays bioRxivpreprint Medium
2023 UBE2Q1 (an E2 ubiquitin-conjugating enzyme) can interact with B4GALT1 protein as demonstrated by co-immunoprecipitation in colorectal cancer cells overexpressing UBE2Q1, and molecular docking confirmed high-affinity interaction between the UBC domain of UBE2Q1 and B4GALT1. Co-immunoprecipitation (IP/silver staining), molecular docking (MOE software) Protein and peptide letters Low 37198983
2020 In bone marrow stromal cells, B4GALT1 expression is positively regulated by the upstream transcription factor c-Jun (via JNK/c-Jun pathway), validated by dual luciferase reporter assay. Overexpression of B4GALT1 in stromal cells promoted proliferation of co-cultured AML cells. Dual luciferase reporter assay, JNK/c-Jun inhibitor treatment, co-culture proliferation assay by flow cytometry Zhongguo shi yan xue ye xue za zhi Low 32027290
2021 In myeloproliferative neoplasm megakaryocytes, increased B4GALT1 expression leads to elevated LacNAc (β4-N-acetyllactosamine/Galβ1,4GlcNAc) expression on platelets, which promotes hepatic thrombopoietin (TPO) synthesis independently of platelet mass, linking B4GALT1-mediated galactosylation to TPO regulation. B4GALT1 gene expression analysis in patient megakaryocytes, LacNAc expression assays on platelets, JAK1/2 inhibitor treatment experiments Blood Medium 33238000

Source papers

Stage 0 corpus · 39 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2023 B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma. Journal of experimental & clinical cancer research : CR 66 37303063
2018 LncRNA B4GALT1-AS1 recruits HuR to promote osteosarcoma cells stemness and migration via enhancing YAP transcriptional activity. Cell proliferation 62 30182452
2020 Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110. Cancer letters 42 33309857
2019 lncRNA B4GALT1-AS1 promotes colon cancer cell stemness and migration by recruiting YAP to the nucleus and enhancing YAP transcriptional activity. Journal of cellular physiology 38 30912138
2019 Assembly of B4GALT1/ST6GAL1 heteromers in the Golgi membranes involves lateral interactions via highly charged surface domains. The Journal of biological chemistry 38 31395657
2016 MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML. Journal of hematology & oncology 34 27516205
2016 Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma. Oncotarget 29 27092876
2018 CRISPR/Cas9-Multiplexed Editing of Chinese Hamster Ovary B4Gal-T1, 2, 3, and 4 Tailors N-Glycan Profiles of Therapeutics and Secreted Host Cell Proteins. Biotechnology journal 25 29862652
2021 Genetic and functional evidence links a missense variant in B4GALT1 to lower LDL and fibrinogen. Science (New York, N.Y.) 24 34855475
2012 B4GALT1 gene knockdown inhibits the hedgehog pathway and reverses multidrug resistance in the human leukemia K562/adriamycin-resistant cell line. IUBMB life 23 23024026
2020 The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression. Journal of cellular and molecular medicine 22 32902124
2019 B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells. Journal of clinical medicine 22 31717588
2018 The dimeric structure of wild-type human glycosyltransferase B4GalT1. PloS one 21 30352055
2015 Multifaceted roles of 5'-regulatory region of the cancer associated gene B4GALT1 and its comparison with the gene family. International journal of oncology 21 26315939
2011 B4GALT1-congenital disorders of glycosylation presents as a non-neurologic glycosylation disorder with hepatointestinal involvement. The Journal of pediatrics 19 21920538
2020 B4GalT1 Regulates Apoptosis and Autophagy of Glioblastoma In Vitro and In Vivo. Technology in cancer research & treatment 18 33287670
2021 Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs. Blood 16 33238000
2023 Decreased B4GALT1 promotes hepatocellular carcinoma cell invasiveness by regulating the laminin-integrin pathway. Oncogenesis 14 37907465
2020 B4GALT1-congenital disorders of glycosylation: Expansion of the phenotypic and molecular spectrum and review of the literature. Clinical genetics 10 32157688
2019 Reduced CETP glycosylation and activity in patients with homozygous B4GALT1 mutations. Journal of inherited metabolic disease 10 31800099
2024 B4GALT1-dependent galectin-8 binding with TGF-β receptor suppresses colorectal cancer progression and metastasis. Cell death & disease 9 39231945
2023 In-Depth Mass Spectrometry Analysis Reveals the Plasma Proteomic and N-Glycoproteomic Impact of an Amish-Enriched Cardioprotective Variant in B4GALT1. Molecular & cellular proteomics : MCP 8 37328064
2022 LncRNA B4GALT1-AS1 promotes non-small cell lung cancer cell growth via increasing ZEB1 level by sponging miR-144-3p. Translational cancer research 8 35402178
2022 B4GALT1 as a New Biomarker of Idiopathic Pulmonary Fibrosis. International journal of molecular sciences 8 36499368
2021 Identification of novel single-nucleotide polymorphism at exon1 and 2 region of B4GALT1 gene and its association with milk production traits in crossbred cattle of Kerala, India. Animal biotechnology 6 33427026
2020 Long non-coding RNA B4GALT1-Antisense RNA 1/microRNA-30e/SRY-box transcription factor 9 signaling axis contributes to non-small cell lung cancer cell growth. Oncology letters 6 33014162
2022 The B-Cell-Specific Ablation of B4GALT1 Reduces Cancer Formation and Reverses the Changes in Serum IgG Glycans during the Induction of Mouse Hepatocellular Carcinoma. Cancers 5 35267641
2024 Downregulation of long noncoding RNA B4GALT1-AS1 is associated with breast cancer development. Scientific reports 3 38326326
2019 Identification of the complete coding cDNAs and expression analysis of B4GALT1, LALBA, ST3GAL5, ST6GAL1 in the colostrum and milk of the Garganica and Maltese goat breeds to reveal possible implications for oligosaccharide biosynthesis. BMC veterinary research 3 31852463
2025 SPOP/NOLC1/B4GALT1 signaling axis enhances paclitaxel resistance in endometrial cancer by inducing O-dysglycosylation. Oncogene 2 40097806
2025 Cytosolic UDP-Gal biosynthetic machinery is required for dimerization of SLC35A2 in the Golgi membrane and its interaction with B4GalT1. Frontiers in molecular biosciences 2 40230451
2016 ZFX modulates the growth of human leukemic cells via B4GALT1. Acta biochimica et biophysica Sinica 2 27797721
2023 Analysis of the Interaction of UBE2Q1 with B4GALT1 and P53: Experimental and Molecular Modeling Study. Protein and peptide letters 1 37198983
2026 B4GALT1 deficiency attenuates steatohepatitis by regulating the PPARγ/ACSL4 axis. Hepatology communications 0 41860570
2026 B4GALT1 drives osteoarthritis progression by stabilizing IL-1R1 through N-linked glycosylation. Cellular signalling 0 42002123
2026 Nascent Pre-Platelets and B4GALT1 Glycosylation Contribute to 5-FU-induced Bone Marrow Recovery. Blood advances 0 42200454
2025 Bioinformatics prediction and experimental verification identify B4GALT1 as a diagnostic biomarker of glioblastoma. International journal of biological macromolecules 0 40460949
2025 B4GALT1 and Wntless collaborate to block LRP5/6 translocation from Golgi to cell surface. The Journal of cell biology 0 41182165
2020 [Effect of B4GALT1 on Proliferation of Its Co-cultured Human Acute Myeloid Leukemia Cell Line in Bone Marrow Stromal Cells]. Zhongguo shi yan xue ye xue za zhi 0 32027290

Missed literature

Know a paper Affinage missed for B4GALT1? Flag it for the maintainers and the community.

No submissions yet.